Klein Sara
Known title: General Counsel - Corp SecyCIK: 0002022981
Associated companies
Transaction History
| ALMS | ▼ Sell | Other | 33,796 | — | 7/1/2024 | View on chart |
| ALMS | ▲ Buy | Grant | 33,796 | — | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 33,796 | — | 7/1/2024 | View on chart |
| ALMS | ▲ Buy | Grant | 33,796 | — | 7/1/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.